Home/Pipeline/Early Disease Detection Signature Discovery

Early Disease Detection Signature Discovery

Cancer

DiscoveryActive

Key Facts

Indication

Cancer

Phase

Discovery

Status

Active

Company

Hummingbird Diagnostics

About Hummingbird Diagnostics

Hummingbird Diagnostics is a privately held, Heidelberg-based biotech founded in 2016, pioneering a novel diagnostic approach. The company's technology platform, mirCator, analyzes small RNAs from whole blood to capture signals from both the disease and the immune system's response, powered by proprietary AI and machine learning software. This integrated analysis aims to create highly sensitive and robust blood tests for early detection and management of cancer and other diseases. The company is in the development stage, building its platform and biomarker database with a seasoned leadership team from diagnostics and computational biology.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active